Physician profile
Sonela Skenderi
NPI 1275733669
$1,813.02
in general payments reported to CMS, 2019-2025
24 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $34.80 · 2021: $114 · 2022: $345 · 2023: $335 · 2024: $364 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $218.20 | 2019-2023 | Watchman Access System |
| Abbott Laboratories | $214.59 | 2022-2024 | Mitraclip |
| Edwards Lifesciences Corporation | $187.33 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $157.26 | 2021-2025 | |
| Pfizer INC. | $138.83 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $122.33 | 2019 | |
| Irhythm Technologies, INC. | $85.53 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Amgen INC. | $78.90 | 2022-2024 | Repatha |
| Merck Sharp & Dohme LLC | $65.60 | 2022-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.42 | 2021-2022 | |
| Biosense Webster, INC. | $62.50 | 2025 | Carto 3 |
| Impulse Dynamics (USA) INC. | $51.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $49.27 | 2019-2022 | |
| Abiomed | $42.66 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $41.83 | 2021-2023 | Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $34.26 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $32.47 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.96 | 2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $27.76 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.43 | 2025 | Onpattro |
| Heartflow, INC. | $22.47 | 2025 | |
| Inari Medical, INC. | $19.94 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $19.87 | 2023 | |
| Novo Nordisk INC | $17.48 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonela Skenderi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.